An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib

Clinical Cancer Research

Volumn 22, Issue 6, 2016, Pages 1325-1329

  Danial, Christina ^a   Sarin, Kavita Y ^a   Oro, Anthony E ^a   Chang, Anne Lynn S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMOOTHENED PROTEIN; SONIDEGIB; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; PYRIDINE DERIVATIVE; SMO PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTIVE SURGERY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LOSS OF APPETITE; MALE; MENTAL HEALTH; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; SMO GENE; TREATMENT DURATION; TUMOR BIOPSY; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, BASAL CELL; CHEMISTRY; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULAR MODEL; MUTATION; PATHOLOGY; PROTEIN CONFORMATION; RETREATMENT; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CARCINOMA, BASAL CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; NEOPLASM STAGING; PROTEIN CONFORMATION; PYRIDINES; RETREATMENT; SKIN NEOPLASMS; SMOOTHENED RECEPTOR; TREATMENT OUTCOME;

EID: 84962269076     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1588     Document Type: Article

References (12)

1. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.NEngl J Med 2012;366:2171-9.
2. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 2014;70:60-9.
3. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol 2012;148:1324-5.
4. Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in Basal cell carcinoma. Cancer Cell 2015;27:327-41.
5. Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in Basal cell carcinoma. Cancer Cell 2015;27:342-53.
6. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 2014;20:1900-9.
7. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced ormetastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015;16:716-28.
8. Wang C,WuH, Katritch V, Han GW, Huang XP, Liu W, et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature 2013;497:338-43.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
10. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5-11.pdf.
11. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4.
12. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2.